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Abstract  This  ISAAC  Phase  Three  synthesis  provides  summarised  information  on  the  main  ﬁnd-
ings of  the  study,  regional  tables  and  ﬁgures  related  to  the  prevalence  and  severity  of  current
symptoms  of  asthma,  rhinoconjunctivitis  and  eczema  in  the  main  regions  of  the  world.  The  large
number of  surveyed  children  (≈1,200,000),  the  large  number  of  centres  (233)  and  countries  (98)
that participated  in  ISAAC  Phase  Three  makes  this  study  the  most  comprehensive  survey  of  these
diseases ever  undertaken.  Globally,  the  prevalence  for  current  asthma,  rhinoconjunctivitis  and
eczema in  the  13--14-year  age  group  was  14.1%,  14.6%  and  7.3%,  respectively.  In  the  6--7-year
age group  the  prevalence  for  current  asthma,  rhinoconjunctivitis  and  eczema  was  11.7%,  8.5%
and 7.9%,  respectively.  The  study  shows  a  wide  variability  in  the  prevalence  and  severity  of
asthma,  rhinoconjunctivitis  and  eczema  which  occurs  not  just  between  regions  and  countries
but between  centres  in  the  same  country  and  centres  in  the  same  city.  This  study  deﬁnitively
establishes  that  the  prevalence  of  those  diseases  can  be  very  high  in  non-afﬂuent  centres  with
low socioeconomic  conditions.  The  large  variability  also  suggests  a  crucial  role  of  local  envi-
ronment characteristics  to  determine  the  differences  in  prevalence  between  one  place  and
another.  Thus,  ISAAC  Phase  Three  has  provided  a  large  body  of  epidemiological  information
on asthma,  rhinoconjunctivitis  and  eczema  in  childhood  from  contrasting  environments  which
loaded from http://www.elsevier.es, day 24/04/2015. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.is expected  to  yield  new  clues  about  the  aetiology  of  those  conditions  and  reasons  for  their
marked global  variability.
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sthma,  rhinoconjunctivitis  and  eczema  in  childhood  have
ecome  three  of  the  more  important  public  health  prob-
ems  worldwide.  Although  in  the  past  it  was  thought  that
hese  diseases  occurred  more  frequently  in  populations  from
eveloped  countries,  it  has  been  evident  since  the  ﬁrst
lobal  report  from  the  International  Study  of  Asthma  and
llergies  in  Childhood  (ISAAC)  that  prevalence  of  those  con-
itions  in  some  low-resourced  countries  was  similar  or  even
igher  than  in  developed  ones  and  that  a  wide  variability  in
heir  prevalence  occurred  at  regional  and  even  at  country
evel.1--4
Since  then,  a  large  body  of  new  national,  regional  and
lobal  information  on  the  prevalence,  severity,  risk  fac-
ors,  trends  and  several  other  aspects  related  to  asthma,
hinoconjunctivitis  and  eczema  in  childhood,  has  been
eported  by  ISAAC.5 The  recently  completed  third  ISAAC
hase  included  the  largest  number  of  centres  from  the  main
orld  regions  ever  studied  in  regard  to  these  conditions,
ith  about  1,200,000  schoolchildren  surveyed;  detailed
nformation  on  the  global  prevalence  and  severity  of  asthma,
hinitis  and  eczema  has  been  reported  in  the  ISAAC  world
ap  journal  articles.6--8
The  well-known  methodological  consistency  of  the  ISAAC
rogramme,  its  originality  and  especially  the  inclusion  of
ountries  with  different  cultures,  socioeconomic  develop-
ent  and  lifestyles,  has  led  to  its  results  being  employed  by
everal  governmental  and  academic  institutions  at  country
nd  regional  level.  It  has  constituted  the  epidemiologi-
al  basis  for  many  of  the  well-known  global  initiatives  on
sthma,  rhinitis  and  eczema  management  in  childhood,
nd  for  guidelines  and  recommendations  from  international
ealth  organisations.
a
c
u
G
igure  1  Geospatial  distribution  of  prevalence  of  current  symptom
ymbol represents  a  centre.  The  four  symbols  depict  different  levels
s afﬂuent  or  non-afﬂuent.  Red  stars  indicate  high  prevalence  of  cu
ellow diamonds  indicate  high  prevalence  of  current  symptoms  of  a
f current  symptoms  of  asthma  and  afﬂuent;  and  blue  squares  indi
fﬂuent. (For  interpretation  of  the  references  to  colour  in  this  ﬁg
rticle.)J.  Mallol  et  al.
This  article  presents  new  information  on  disease  over-
ap  (asthma,  rhinoconjunctivitis,  eczema),  socioeconomic
nd  geospatial  considerations  from  ISAAC  Phase  Three  (writ-
en  questionnaires)  concerning  the  prevalence  of  asthma,
hinoconjunctivitis  and  eczema  in  children  aged  6--7  and
3--14  years.
ethods
he  detailed  methodology  employed  by  ISAAC  to  obtain  and
nalyse  data  for  Phase  Three,  has  already  been  published
n  detail  elsewhere.5,9 Brieﬂy,  written  questionnaires  were
elf-completed  at  school  by  13--14-year  olds  and  completed
t  home  by  parents  of  6--7-year  olds.  Samples  of  3000  chil-
ren  for  each  age  group  (with  a  minimum  of  1000)  within
ach  centre  were  selected  by  randomly  sampling  schools
ithin  the  study  area.  Almost  all  centres  studied  the  13--14-
ear  age  group,  but  only  some  centres  studied  the  optional
--7-year  age  group.  Data  checks  were  undertaken  by  the
SAAC  International  Data  Centre  in  Auckland,  New  Zealand
hich  ensured  adherence  to  the  protocol.  The  English  lan-
uage  questionnaire  was  translated  where  required,  and  a
ack  translation  to  English  was  provided.  In  this  paper,  we
ocus  on  the  current  symptoms  (past  12  months)  of  asthma,
hinoconjunctivitis  and  eczema;  and  reported  asthma  ever.
Associations  between  prevalence  of  current  symptoms
f  asthma,  rhinoconjunctivitis  and  eczema,  and  a  range
f  geo-climatic  factors  were  assessed  using  maps  pre-
ared  in  the  ArcGIS  geographic  information  system  (version
.3.1,  ESRI  Inc.,  Redlands,  CA,  USA).  The  factors  presented
re  altitude,10 air  pollution  as  indicated  by  the  predicted
oncentrations  (micro  grams  per  cubic  metre)  of  partic-
late  matter  less  than  10  m  in  diameter  (PM10),11 and
ross  National  Income  per  capita  (GNI).12 High  altitude  was
s  of  asthma  and  country  income,  13--14-year  age  group.  Each
 of  prevalence  of  symptoms  combined  with  their  categorisation
rrent  symptoms  of  asthma  (≥10%)  and  afﬂuent  (GNI  >  $9265);
sthma  and  non-afﬂuent;  green  circles  indicate  low  prevalence
cate  low  prevalence  of  current  symptoms  of  asthma  and  non-
ure  legend,  the  reader  is  referred  to  the  web  version  of  the
Synthesis  of  ISAAC  Phase  Three  75
Figure  2  Geospatial  distribution  of  prevalence  of  current  symptoms  of  asthma  and  altitude,  13--14-year  age  group.  Each  symbol
represents a  centre.  The  four  symbols  depict  different  levels  of  prevalence  of  symptoms  combined  with  their  categorisation  as
low or  high  altitude.  Red  stars  indicate  high  prevalence  of  current  symptoms  of  asthma  (≥10%)  and  high  altitude  (≥300  m);  yellow
diamonds indicate  high  prevalence  of  current  symptoms  of  asthma  and  low  altitude;  green  circles  indicate  low  prevalence  of  current
te  low
end,
a
T
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(For interpretation  of  the  references  to  colour  in  this  ﬁgure  leg
deﬁned  as  ≥300  m.  High  PM10 was  deﬁned  as  ≥50  g/m3.
Data  for  altitude  and  air  pollution  were  available  at  centre
level  whereas  the  GNI  data  were  only  available  at  country
level.  Non-afﬂuent  countries  were  those  classiﬁed  by  the
World  Bank  as  low,  lower  middle,  or  upper  middle  income,
h
c
s
Figure  3  Geospatial  distribution  of  prevalence  of  current  sympto
group. Each  symbol  represents  a  centre.  The  four  symbols  depict  di
categorisation as  low  or  high  (PM10).  Red  stars  indicate  high  preva
(≥50  g/m3);  yellow  diamonds  indicate  high  prevalence  of  current  
prevalence of  current  symptoms  of  asthma  and  high  PM10;  and  blue  s
and low  PM10.  (For  interpretation  of  the  references  to  colour  in  this  
article.) prevalence  of  current  symptoms  of  asthma  and  low  altitude.
 the  reader  is  referred  to  the  web  version  of  the  article.)
nd  afﬂuent  countries  are  those  classiﬁed  as  high  income.
he  maps  (Figs.  1--3)  illustrate  the  distribution  of  low  and
igh  values  of  prevalence  and  GNI,  altitude  and  PM10.  For
urrent  symptoms  of  asthma  (current  wheeze)  and  current
ymptoms  of  eczema,  high  prevalence  centres  were  deﬁned
ms  of  asthma  and  particulate  matter  (PM10),  13--14-year  age
fferent  levels  of  prevalence  of  symptoms  combined  with  their
lence  of  current  symptoms  of  asthma  (≥10%)  and  high  PM10
symptoms  of  asthma  and  low  PM10;  green  circles  indicate  low
quares  indicate  low  prevalence  of  current  symptoms  of  asthma
ﬁgure  legend,  the  reader  is  referred  to  the  web  version  of  the
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Table  1  Prevalence  of  current  symptoms  of  asthma,  rhinoconjunctivitis  and  eczema  by  world  region  and  gender,  6--7-year  age
group.
Region Gender  N  Asthma  Rhinoconjunctivitis  Eczema
N % N  %  N  %
Africa Male  2979  321  10.8  223  7.5  283  9.5
Female 2886  268  9.3  230  8.0  262  9.1
Asia-Paciﬁc Male 30,509  3296  10.8  3712  12.2  2962  10.2b
Female  29,470  2423  8.2  2615  8.9  2796  10.0b
Eastern
Mediterranean
Male  20,769  2146  10.3  1130  5.4  1001  4.8
Female 19,804 1678 8.5  968  4.9  943  4.8
Indian
Sub-Continent
Male 25,867 1909 7.4  1166  4.5  786  3.0
Female 24,225  1483  6.1  917  3.8  735  3.0
Latin America Male  45,926  8691  18.9  6017  13.1  4482  9.8
Female 47,848  7565  15.8  5914  12.4  4873  10.2
North America Male  2011  433  21.5  176  8.8  197  9.8
Female 2001  334  16.7  136  6.8  207  10.3
Northern and
Eastern  Europe
Male 21,444  2132  9.9  1277  6.0  1286  6.0
Female 21,104 1583 7.5  1064  5.0  1302  6.2
Oceania Male 7028  1705  24.3  879  12.5  991  14.1
Female 6860  1315  19.2  742  10.8  1163  17.0
Western Europe Male 39,328 4296 10.9  3247  8.3  3018  7.7
Female 38,394 3191 8.3  2491 6.5  3301  8.6
Male Total  195,861  24,929  12.7  17,827  9.1  15,006  7.7b
Female  Total  192,592  19,840  10.3  15,077  7.8  15,582  8.2b
Global  Totala 388,811  44,799  11.5  32,928  8.5  30,616  7.9b
a Includes participants with unknown gender (358).
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s  those  with  prevalence  of  10%  or  greater.  For  current
ymptoms  of  rhinoconjunctivitis,  high  prevalence  centres
ere  deﬁned  as  those  with  prevalence  of  15%  or  greater
or  the  13--14-year  age  group  and  7.5%  or  greater  for  the
--7-year  age  group.  These  deﬁnitions  are  based  on  the  lev-
ls  used  in  the  maps  presented  in  the  ISAAC  prevalence
apers.1--4,6--8 Spearman  correlation  (rho)  was  used  to  study
he  association  of  altitude,  latitude  and  longitude  with  the
revalence  of  current  symptoms  of  asthma,  rhinoconjunc-
ivitis  and  eczema.
Spearman’s  correlation  (rho)  was  employed  to  deter-
ine  associations  between  current  symptoms  of  asthma,
hinoconjunctivitis  and  eczema,  with  centre  level  altitude,
atitude,  longitude  and  PM10,  and  with  country  level  GNI,  in
--7-year  and  13--14-year  age  groups.
esults
articipants
SAAC  Phase  Three  surveyed  about  1,200,000  children  from
33  centres  in  98  countries,  involving  almost  800,000  chil-
ren  aged  13--14  years  and  almost  400,000  aged  6--7  years.
or  asthma  the  data  sets  comprised  1,187,496  schoolchil-
ren  from  233  centres  in  98  countries,  of  whom  128  centres
b
e
i
Atres included the eczema questionnaire.
689,413  participants)  in  64  countries  (34  countries  new
o  ISAAC)  had  not  undertaken  ISAAC  Phase  One;  798,685
ere  aged  13--14  years  and  388,811  were  aged  6--7  years.
he  majority  of  the  new  ISAAC  centres  were  from  coun-
ries  in  Latin  America,  Eastern  Europe  and  Africa,  although
here  were  also  some  from  other  regions.7 In  the  case
f  rhinoconjunctivitis,  the  13--14-year  age  group  involved
70,242  children  and  388,811  children  aged  6--7  years.
egarding  eczema,  for  the  13--14-year  age  group  there  were
63,256  children  and  385,853  for  the  6--7-year  age  group.8
f  the  54  languages  used  in  Phase  Three,  English  was  the
ost  common  (21%  of  centres)  followed  by  Spanish  (20%),
ortuguese  (11%),  Arabic  (7%),  Italian  (6%),  French  (5%)  and
hinese  (4%).  The  number  of  participating  centres  per  region
anged  from  seven  in  North  America  to  56  in  Latin  America.
ymptoms  by  region  and  gender
he  regional  prevalences  of  current  symptoms  for  the  three
onditions  are  shown  in  Tables  1  and  2  by  gender.
There  was  large  variability  of  prevalence  between
egions  for  symptoms  of  each  of  the  three  conditions  and
oth  age  groups.  For  the  younger  age  group  the  low-
st  prevalence  values  for  asthma  symptoms  were  found
n  the  Indian  Subcontinent,  with  intermediate  values  in
frica,  Asia-Paciﬁc,  Eastern  Mediterranean,  Northern  and
Synthesis  of  ISAAC  Phase  Three  77
Table  2  Prevalence  of  current  symptoms  of  asthma,  rhinoconjunctivitis  and  eczema  by  region  and  gender,  13--14-year  age
group.
Region Gender  N  Asthma  Rhinoconjunctivitis  Eczema
N % N  %  N  %
Africa Male  32,373  4521  14.0  5087  15.7  3822  11.8
Female 33,935  4747  14.0  6850  20.2  4640  13.7
Asia-Paciﬁc Male 49,675  4428  8.9  6208  12.5  2174  4.7b
Female  49,959  4303  8.6  7498  15.0  2692  5.8b
Eastern
Mediterranean
Male  25,879  2748  10.6  3393  13.1  1627  6.3
Female 25,826 2053 7.9  3361  13.0  1615  6.3
Indian
Sub-Continent
Male 27,432 2362 8.6  3203  11.7  1218  4.4
Female 28,351  1522  5.4  2762  9.7  916  3.2
Latin America Male  80,715  11,753  14.6  11,193  13.9  5062  6.3
Female 85,185  14,597  17.1  17,543  20.6  8631  10.1
North America Male  69,739  13,793  19.8  906  13.8b 421  6.4b
Female  71,270  16,634  23.3  1445  19.6b 693  9.4b
Northern  and
Eastern  Europe
Male 35,455  3168  8.9  2721  7.7  1356  3.8
Female 36,602 3841 10.5  3873  10.6  2308  6.3
Oceania Male 17,837  3060  17.2  2620  14.7  1520  8.5
Female 18,462  3241  17.6  3547  19.2  2028  11.0
Western Europe Male 54,741 7545 13.8  6771  12.4  2968  5.4
Female 52,932 7938 15.0  8835 16.7  4414  8.3
Male Total  Male  393,846  53,378  13.6  42,102  12.7b 20,168  6.2b
Female  Total  Female  402,522  58,876  14.6  55,714  16.5b 27,937  8.3b
Global  Totala 798,685  112,630  14.1  97,866  14.6b 48,131  7.3b
a Includes participants with unknown gender (2317).
b Percent values calculated using smaller denominators as not all centres included the rhinoconjunctivitis and eczema questionnaires.
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els  in  Latin  America,  North  America,  and  Oceania.  The
lowest  prevalence  values  for  rhinoconjunctivitis  symptoms
were  found  in  Eastern  Mediterranean,  Indian  Subcontinent,
and  Northern  and  Eastern  Europe,  with  intermediate  val-
ues  in  Africa,  Asia-Paciﬁc,  and,  Western  Europe,  and  the
highest  in  Latin  America,  North  America,  and  Oceania.
The  lowest  prevalence  values  for  symptoms  of  eczema
were  found  in  Eastern  Mediterranean,  Indian  Subconti-
nent,  with  intermediate  values  in  Africa,  Asia-Paciﬁc,
and  Northern  and  Eastern  Europe,  Western  Europe,  North
America,  and  the  highest  values  in  Latin  America,  and
Oceania.
For  the  older  age  group  the  lowest  prevalence  values
for  asthma  symptoms  were  found  in  Asia-Paciﬁc,  Eastern
Mediterranean,  Indian  Subcontinent,  and  Northern  and  East-
ern  Europe,  with  intermediate  values  in  Africa  and  Oceania,
Western  Europe,  and  Latin  America,  and  the  highest  in
North  America.  The  lowest  prevalence  values  for  rhinocon-
junctivitis  symptoms  were  found  in  Indian  Subcontinent,
and  Northern  and  Eastern  Europe,  with  intermediate  val-
ues  in  Asia-Paciﬁc,  Eastern  Mediterranean,  Oceania  and
Western  Europe,  and  the  highest  values  in  Africa,  Latin
America,  and  North  America.  The  lowest  prevalence  values
for  symptoms  of  eczema  were  found  in  Asia-Paciﬁc,  Eastern
t
s
t
eediterranean,  Indian  Subcontinent,  and  Northern  and  East-
rn  Europe,  with  intermediate  values  in  Latin  America,
ceania,  North  America,  and  Western  Europe,  and  the  high-
st  values  in  Africa.
The  summaries  by  gender  for  symptoms  of  each  of  the
hree  diseases  and  both  age  groups  showed  that  in  the
ounger  age  group  there  were  more  boys  than  girls  with
sthma  and  rhinoconjunctivitis  symptoms,  and  this  held  true
or  all  regions  for  asthma,  and  most  for  rhinoconjunctivitis
ymptoms,  but  eczema  symptoms  overall  were  more  com-
on  in  girls  although  this  varied  across  the  regions.  In  the
lder  age  group  there  were  more  girls  than  boys  with  symp-
oms  of  all  three  conditions,  and  this  held  true  for  most
egions.
oncurrent  prevalence  of  symptoms  of  current
sthma, rhinoconjunctivitis  and  eczema
 low  proportion  of  children  simultaneously  reported  cur-
ent  symptoms  of  asthma,  rhinoconjunctivitis  and  eczema.
mongst  the  world  regions  there  was  a large  variability  in
he  prevalence  of  the  three  diseases;  for  those  with  current
ymptoms  of  asthma  the  prevalence  for  the  concurrence  of
he  three  conditions  varied  from  6.3%  in  Northern  and  East-
rn  Europe  to  13.6%  in  Africa  in  the  13--14  years  old  group
78  J.  Mallol  et  al.
Table  3  Prevalence  of  current  symptoms  of  asthma  only  with  associated  co-morbidities,  6--7-year  age  group.
Current
wheeze
Asthma  only  Asthma  and
rhinoconjunctivitis
Asthma  and
eczema
All  3
conditions
N %a %a %a %a
Africa  590  60.3  15.1  12.7  11.9
Asia-Paciﬁc 5186  57.4  21.5  11.5  9.5
Eastern Mediterranean  3824  73.6  13.2  8.0  5.2
Indian Sub-Continent 3395  72.6  16.3  5.9  5.1
Latin America 16,266 59.8  21.6  9.4  9.1
North America 767 66.9  13.0  11.7  8.3
Northern and  Eastern  Europe 3717 68.7  15.3  9.6  6.4
Oceania 3020 56.9  16.1  15.6  11.4
Western Europe  7497  60.5  20.1  10.6  8.8
a Percentage of participants with current wheeze.
Table  4  Prevalence  of  current  symptoms  of  asthma  only  with  associated  co-morbidities,  13--14-year  age  group.
Current
wheeze
Asthma  only  Asthma  and
rhinoconjunctivitis
Asthma  and
eczema
All  3
conditions
N %a %a %a %a
Africa  9275  51.0  24.5  10.9  13.6
Asia-Paciﬁc 8037  60.4  26.6  6.4  6.6
Eastern Mediterranean  4801  60.9  23.5  7.1  8.5
Indian Sub-Continent  3894  61.5  23.1  5.2  10.1
Latin America  26,352  57.1  26.9  7.0  9.0
North America  2337  55.6  27.9  7.3  9.1
Northern and  Eastern  Europe  7012  64.7  21.6  7.3  6.3
Oceania 6306  58.6  23.7  8.7  9.0
Western Europe  15,503  58.3  25.6  8.1  7.9
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nd  from  5.1%  in  the  Indian  Subcontinent  to  11.9%  in  Africa
n  those  aged  6--7  years.  The  relative  proportions  for  the
egional  concurrent  prevalence  of  the  three  diseases  are
resented  in  Tables  3--8.The  global  prevalence  of  current  symptoms  of  the  three
iseases  reported  simultaneously  by  children  is  shown  in
ig.  4.
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Table  5  Prevalence  of  current  symptoms  of  rhinoconjunctivitis  w
Rhinoconjunctivitis Rhinoconjunct
only
N %a
Africa  454  47.4  
Asia-Paciﬁc 6015  58.5  
Eastern Mediterranean  2098  57.2  
Indian Sub-Continent  2085  56.7  
Latin America  11,940  45.4  
North America  312  35.6  
Northern and  Eastern  Europe  2343  54.0  
Oceania 1621  35.0  
Western Europe 5746 48.9  
a Percentage of participants with current symptoms of rhinoconjunctrevalence  in  centres  related  to  socioeconomic
tatus  of  countries
n  both,  the  6--7  and  13--14-year  age  groups,  GNI  was  pos-
tively  correlated  (Spearman’s  rho)  with  current  symptoms
f  asthma,  rhinoconjunctivitis  and  eczema  (Table  9).  The
eospatial  distribution  of  current  symptoms  of  asthma  and
ith  associated  co-morbidities,  6--7-year  age  group.
ivitis Rhinoconjunctivitis
and  asthma
Rhinoconjunctivitis
and  eczema
All  3
conditions
%a %a %a
19.6  17.6  15.4
18.6  14.7  8.2
24.1  9.2  9.5
26.6  8.3  8.3
29.5  12.7  12.4
32.1  11.9  20.5
24.3  11.5  10.2
30.0  13.8  21.2
26.2  13.3  11.5
ivitis.
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Table  6  Prevalence  of  current  symptoms  of  rhinoconjunctivitis  with  associated  co-morbidities,  13--14-year  age  group.
Rhinoconjunctivitis  Rhinoconjunctivitis
only
Rhinoconjunctivitis
and  asthma
Rhinoconjunctivitis
and  eczema
All  3
conditions
N %a %a %a %a
Africa  11,943  53.5  19.0  16.9  10.6
Asia-Paciﬁc 12,310  69.7  17.3  8.6  4.3
Eastern Mediterranean  6754  66.1  16.7  11.2  6.0
Indian Sub-Continent  5968  70.0  15.1  8.3  6.6
Latin America  28,738  55.8  24.6  11.3  8.2
North America  2354  53.9  27.7  9.3  9.0
Northern and  Eastern  Europe 6599 61.5  23.0  8.8  6.7
Oceania 6179 53.7  24.2  12.9  9.2
Western Europe 15,619 58.7  25.4  8.0  7.9
a Percentage of participants with current symptoms of rhinoconjunctivitis.
Table  7  Prevalence  of  current  symptoms  of  eczema  with  associated  co-morbidities,  6--7-year  age  group.
Current
eczema
Eczema  only  Eczema  and
asthma
Eczema  and
rhinoconjunctivitis
All  3
conditions
N %a %a %a %a
Africa  546  58.8  13.7  14.7  12.8
Asia-Paciﬁc 5762  65.7  10.4  15.3  8.6
Eastern Mediterranean  1944  64.1  15.7  10.0  10.2
Indian Sub-Continent  1521  63.8  13.3  11.4  11.4
Latin America  9363  51.7  16.3  16.2  15.8
North America  405  52.8  22.2  9.1  15.8
Northern and  Eastern  Europe  2595  66.7  13.7  10.4  9.2
Oceania 2154  51.9  21.9  10.4  15.9
Western Europe  6326  64.9  12.5  12.1  10.5
4,7%
7,2%
Current
symptoms of
asthma
Current
symptoms of
rhinoconjunctivitis
Current
symptoms of
eczema
73,6% No symptoms
Current
symptoms of
asthma
Current
symptoms of
rhinoconjunctivitis
Current
symptoms of
eczema
B
8,7%
3,2%
7,3%
1,1% 1,6%
3,6%
1,0%
4,2%
2,2%
1,0% 1,1%
1,1%
78,5% No symptoms
A
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GNI  is  shown  in  Fig.  1.  There  are  four  patterns  of  centres
shown:  a  high  prevalence  in  afﬂuent  centres;  a  high  preva-
lence  in  non-afﬂuent  centres;  a  low  prevalence  in  afﬂuent
centres;  and  a  low  prevalence  in  non-afﬂuent  centres.
Geo-climatic  factors  and  their  relationship  with
current prevalence  of  asthma,  rhinoconjunctivitis
and eczema
Globally,  it  was  found  that  lower  latitudes  and  East-
ern  longitudes  were  slightly  but  signiﬁcantly  associated
with  higher  prevalence  of  current  symptoms  of  asthma,
and  rhinoconjunctivitis  and  eczema  in  both  age  groups
(Table  9).  However,  this  was  not  a  consistent  ﬁnding.  For
instance,  in  large  regions  including  both  hemispheres  as
Latin  America,  no  signiﬁcant  association  was  found  between
latitude/longitude  and  prevalence  of  current  symptoms.
The  mean  prevalence  of  the  three  diseases  was  similar  in
centres  located  in  tropical  versus  non-tropical  areas.  The
distribution  of  prevalence  of  current  symptoms  by  alti-
tude  in  the  group  aged  13--14  years  (Fig.  5)  showed  a
weak  but  signiﬁcant  inverse  correlation  just  for  current
asthma  but  not  for  rhinoconjunctivitis  or  eczema;  in  the
6--7-year  age  group  there  was  a  weak  but  signiﬁcant  inverse
Figure  4  Overall  proportions  of  children  with  current
symptoms  of  asthma,  rhinoconjunctivitis,  or  eczema,  or  com-
binations  of  symptoms,  6--7-year  age  group  (A)  and  13--14-year
age group  (B)  for  ISAAC  Phase  Three.
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Table  8  Prevalence  of  current  symptoms  of  eczema  with  associated  co-morbidities,  13--14-year  age  group.
Current
eczema
Eczema  only  Eczema  and
asthma
Eczema  and
rhinoconjunctivitis
All  3
conditions
N %a %a %a %a
Africa  8466  49.3  11.9  23.9  15.0
Asia-Paciﬁc 4868  56.7  10.6  21.9  10.9
Eastern Mediterranean  3242  53.5  10.6  23.3  12.6
Indian Sub-Continent  2136  48.7  9.6  23.2  18.5
Latin America  13,694  45.4  13.5  23.8  17.3
North America  1117  46.0  15.3  19.6  19.1
Northern and  Eastern  Europe 3665 58.0  13.9  15.9  12.1
Oceania 3555 46.3  15.4  22.4  15.9
Western Europe 7388 49.4  17.1  16.9  16.6
a Percentage of participants with current symptoms of eczema.
Table  9  Associations  (Spearman’s  rho)  between  current  symptoms  of  asthma,  rhinoconjunctivitis  and  eczema,  with  centre
level altitude,  latitude,  longitude  and  PM10,  and  with  country  level  GNI,  in  6--7-year  (144  centres)  and  13--14-year  age  groups
(233 centres).
Asthma  Rhinoconjunctivitis  Eczema
rho  p  rho  p  rho  p
6--7  year  age  group
Altitude −0.236  0.005  −0.045  0.593  −0.186  0.027
Latitude −0.369 <0.001  −0.383  <0.001  −0.210  0.012
Longitude −0.356 <0.001  −0.402  <0.001  −0.201  0.016
GNI 0.244 0.004  0.328  <0.001  0.464  <0.001
13--14-year age  group
Altitude  −0.130  0.047  −0.062  0.349  −0.113  0.087
Latitude −0.274  <0.001  −0.249  <0.001  −0.188  0.004
Longitude −0.380  <0.001  −0.265  <0.001  −0.262  <0.001
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amongst  New  York  neighbourhoods,  with  a  3--19%  difference
in  asthma  prevalence  across  the  city  associated  with  varia-
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elationship  between  altitude,  asthma  and  eczema  but  not
ith  rhinoconjunctivitis  (Table  9).
articulate  matter  less  than  or  equal  to  10  m
PM10)  and  the  relationship  with  current
revalence  of  asthma,  rhinoconjunctivitis  and
czema
verall,  ISAAC  Phase  Three  found  that  PM10 showed  a  trend
o  be  inversely  related  with  current  symptoms  of  asthma,
hinoconjunctivitis  and  eczema  at  level  centre;  however,
he  relationship  was  inconsistent  or  null  at  within-country
evel.
iscussion
his  is  the  largest  study  of  asthma,  rhinoconjunctivitis  and
czema  ever  conducted,  and  the  ﬁrst  time  that  the  relation-
hip  between  the  three  diseases,  and  various  geospatial  and
eo-climatic  phenomena  has  been  examined.  ISAAC  Phase
hree  was  performed  in  all  WHO  regions  thus  the  main  con-
inents  and  ethnic  areas  of  the  world  were  represented  in
he  study.
F
a
p6  0.002  0.203  0.003
The large  variability  of  prevalence  between  regions,  con-
inents,  countries,  centres  in  the  same  country,  and  even
etween  centres  in  the  same  city  (as  in  Mexico  City)  is  prob-
bly  the  main  and  most  consistent  ﬁnding  of  ISAAC.6--8 The
arked  difference  of  prevalence  between  centres  in  the
ame  city,  as  occurred  in  Mexico  City,  has  also  been  foundigure  5  Associations  between  prevalence  of  current  wheeze
nd altitude  in  ISAAC  Phase  Three,  6--7-year  (rho  −0.24,
 =  0.005)  and  13--14-year  (rho  −0.13  p  =  0.047)  age  groups.
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impact  of  still  undeﬁned  local  environmental  or  ecologic
factors  present  at  each  centre,  which  may  determine  vary-
ing  epidemiological  and  clinical  expressions  of  diseases  in
populations  at  similar  settings.14--16 The  latter,  i.e.  the  inﬂu-
ence  of  local  variation  in  exposures  on  prevalence,  seems
to  be  supported  by  the  large  variability  found  amongst  cen-
tres  in  the  prevalence  of  allergen  sensitisation 17 and  airway
hyperresponsiveness.18
Although  the  whole  study  found  a  subtle  relationship
between  GNI  and  overall  symptom  prevalence,  in  large
regions  such  as  Latin  America  (56  centres  in  17  countries),
which  accounted  for  about  25%  of  all  the  children  surveyed
by  ISAAC  Phase  Three  in  the  world,19 there  was  not  a  sig-
niﬁcant  correlation  between  GNI  and  prevalence.  Using  the
GNI  or  other  country-average  index  to  study  the  effect  of
socioeconomic  status  on  the  prevalence  of  current  symp-
toms,  especially  when  including  centres  from  afﬂuent  and
non-afﬂuent  countries,  may  be  misleading,  since  the  income
distribution  in  developing  countries  is  highly  unequal.  There-
fore,  assigning  the  GNI  of  a  developing  country  to  all
centres  in  that  country  would  be  inadequate  because  the
risk  of  losing  the  large  differences  in  income  distribution
between  centres  in  developing  countries,  and  regions.20
Until  socioeconomic  data  at  an  individual  level  are  available
for  all  participating  centres,  the  effect  of  socioeconomic
development  on  the  prevalence  and  severity  of  asthma,
rhinoconjunctivitis  and  eczema  will  be  bedevilled  by  this
methodological  issue.  The  results  of  studies  looking  at  the
relationship  between  socioeconomic  status  and  prevalence
of  symptoms  vary  from  an  inverse  association,21--24 to  no
association25 to  a  positive  association26;  apart  from  method-
ological  considerations  which  may  reﬂect  the  lack  of  proper
and  standardised  instruments  to  assess  such  associations  at
centre  or  individual  level.
Higher  or  lower  prevalence  of  current  symptoms  of
asthma,  rhinoconjunctivitis  and  eczema  occurred  regardless
of  whether  centres  were  located  in  developing  or  devel-
oped  countries  or  regions,1,2,5--8 and  this  was  consistent
with  the  ﬁndings  of  ISAAC  Phase  One.2 For  instance,  in
Africa  the  13--14-year  age  group  had  the  same  mean  preva-
lence  of  current  wheezing  as  Western  Europe  (14%);  similar
prevalence  of  rhinoconjunctivitis  and  eczema  also  occurred
between  developing  and  developed  countries,  as  shown  in
Tables  1  and  2.  In  general,  most  centres  with  a  high  or
low  prevalence  in  Phase  Three  tended  to  remain  close  to
the  level  of  prevalence  they  had  in  Phase  One;  although
there  were  some  centres  showing  important  increases  or
decreases  between  the  two  phases.  In  areas  sharing  the
same  language  but  different  socioeconomic  development,
the  prevalence  of  current  asthma  symptoms  was  higher  in
developing  than  developed  countries  (i.e.,  Iberian  Peninsula
vs.  Latin  America).19
The  inclusion  of  many  more  centres  from  developing
countries  in  Phase  Three  than  in  Phase  One  is  an  impor-
tant  achievement  of  ISAAC  as  the  proportion  of  the  world
population  that  lives  in  developing  areas  is  about  80%.  This
is  important  because  several  theories  on  asthma  causa-
tion  are  related  to  the  protective  effect  of  factors  usually
associated  with  low  socioeconomic  status.  Considering  that
conditions  of  poverty  have  been  persistently  affecting  pop-
ulations  in  developing  areas  for  a  long  time,  without
dramatic  changes  in  the  last  20  years,  a  lower  prevalence
t
o
p
t81
f asthma,  rhinoconjunctivitis,  and  eczema  would  have
een  expected  in  children  and  adolescents  from  those  low-
esourced  countries.  The  participation  of  many  more  centres
rom  developing  countries  certainly  provides  a  more  realistic
epresentation  of  the  world  prevalence  of  asthma,  rhinocon-
unctivitis  and  eczema  in  childhood.  At  present,  and  thanks
o  the  information  gathered  by  ISAAC,  the  old  statement
hat  asthma  was  just  a  disease  of  industrialised  and  devel-
ped  countries  can  be  considered  simply  as  an  exclusion
ias.
As  in  Phase  One,  most  symptomatic  children  had  symp-
oms  of  only  one  disorder  in  the  previous  year,  which
ndicates  that  many  different  risk  factors  may  be  required
or  the  clinical  expression  of  these  related  disorders  or  may
nvolve  different  time  of  occurrence,  latency  periods  and
ime  trends.
Although  the  proportion  of  subjects  having  the  three
iseases  simultaneously  was  relatively  low,  those  children
robably  represent  a  highly  demanding  group  for  specialised
ealth  care.  Furthermore,  it  is  likely  that  as  seen  in  daily
ractice,  coexistence  of  these  diseases  may  be  associated
ith  greater  functional  impairment  in  terms  of  activity  lim-
tation  and  lower  quality  of  life  as  compared  to  children
ho  have  one  condition  alone.  Co-morbidities  are  impor-
ant  for  clinicians  treating  asthma  as  they  may  be  markers
f  patients  at  risk  of  poor  outcomes,  they  may  point  to  spe-
iﬁc  effective  treatment  options  and  they  are  important  to
esearchers  as  possible  confounding  factors  in  clinical  trials.
The  effect  of  geo-climatic  factors  on  the  current  symp-
om  prevalence  should  be  interpreted  cautiously  because  of
he  dynamic  nature  of  climatic  factors  that  sometimes  act
ndependently  of  latitude  and  longitude,  as  is  apparently
ccurring  in  this  last  decade.  Consequently,  geo-climatic
actors  should  be  considered  as  part  of  a  much  more  complex
odel  interacting  with  several  other  ecological  conditions
hich  also  could  be  altered  by  seasonal  or  yearly  changes.
s  other  authors  previously  found,27,28 ISAAC  Phase  Three
ound  correlations  between  some  geo-climatic  factors  and
he  prevalence  of  asthma,  rhinoconjunctivitis  and  eczema;
owever,  the  interpretation  and  time-dependency  of  such
ffects  remains  difﬁcult  to  understand.
The  complex  relationships  between  air  pollution  and
ymptoms  of  asthma,  rhinoconjunctivitis  and  eczema  prob-
bly  cannot  be  elucidated  from  data  as  those  obtained  by
SAAC.  Further  information  on  the  type,  magnitude  and  tem-
orality  of  exposures,  which  also  consider  variations  caused
y  geo-climatic  (i.e.  seasonal)  factors,  should  help  to  a  bet-
er  understanding  of  the  true  effects  of  air  pollution  on
he  prevalence  of  asthma,  rhinoconjunctivitis  and  eczema
n  children.
imitations
n  some  way,  ISAAC  shares  the  potential  limitations  of
ny  large  multicentre  international  cross-sectional  study
differences  in  language,  socioeconomic  development,
ifestyle,  cultural  standard,  environmental  aspects,  educa-
ional  level,  medical  practice  and  health  concepts,  amongst
thers).  We  acknowledge  the  limitations  of  international
revalence  comparisons  of  this  kind  and  also  of  interpreta-
ions  on  its  ﬁndings.  Another  concern  is  that  centre  GNI  was
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ssumed  to  be  the  same  as  country  GNI.  Unfortunately,  for
ost  of  the  centres  in  developing  countries  or  regions  there
s  no  ofﬁcial  information  available  regarding  socioeconomic
tatus.  At  present,  it  is  clear  that  in  those  countries  or
reas  with  huge  inequities  of  income  distribution 19 the
holesale  application  of  a  country  level  measure  to  all
entres  conceals  more  than  it  reveals.Nevertheless,  the
orldwide  scope  of  ISAAC  Phase  Three  including  centres
cross  the  main  world  regions,  the  use  of  standardised
nd  validated  methodology,  a  meticulous  translation  of
uestionnaires  to  different  languages,29 strict  data  quality
ontrol  and  management,  and  a  thorough  repetition  of  the
tudy  after  several  years,  has  provided  for  the  ﬁrst  time
 unique  and  fundamental  epidemiological  analysis  of  the
orld  distribution  and  trend  of  the  prevalence  and  severity
f  asthma,  rhinoconjunctivitis  and  eczema  in  children.30
t  the  same  time  ISAAC  has  provided  a  stimulus  for  the
evelopment  of  new  hypotheses  and  a  challenge  to  identify
odiﬁable  protective  and  risk  factors  for  asthma,  and
he  other  diseases  studied.  The  worldwide  time  trends
n  the  prevalence  of  current  symptoms  are  not  described
n  the  present  paper  because  they  have  been  extensively
etailed  elsewhere.31--33
As  found  in  ISAAC  Phase  One,  there  was  a  low  degree
f  overlap  between  the  three  conditions2 suggesting  that
sthma,  rhinoconjunctivitis  and  eczema  may  have  differ-
nt  aetiologies,  time  of  occurrence  and  clinical  course,
robably  related  with  particular  enviromental  exposures  at
ach  locality  or  area.The  wide  variability  of  the  prevalence
f  the  studied  diseases,  found  by  ISAAC  in  all  its  phases,
trongly  points  to  local  ecological  factors  or  exposures  which
re  probably  typical  for  each  locality,  as  the  main  deter-
inants  for  the  observed  variability  of  symptoms,  allergic
ensitisation  and  airways  hyperresponsiveness  reported  by
ecent  ISAAC  studies.  The  latter  is  in  accordance  with  cur-
ent  research  on  how  and  when  exposures  to  environmental
gents  can  induce  epigenetic  changes  that  will  result  in  vary-
ng  biological,  clinical  and  epidemiological  expressions  of
sthma  and  allergies.14--16
Another  most  successful  task  of  ISAAC  Phase  Three  was
he  consolidation  of  a  world  research  force  based  on  a huge
cientiﬁc,  trained  and  efﬁcient  network,  throughout  the
ontinents  and  main  regions  of  the  planet  and  despite  the
arked  differences  in  cultural  and  environmental  aspects
mongst  participating  countries  and  centres.  Ellwood  et  al.
ave  found  that  the  majority  of  centres  in  this  repeat
ulti-centre  international  research  project  undertaken  by
esearchers  with  diverse  cultural  backgrounds  were  able
o  replicate  the  methodology  between  phases  (data  not
hown).
The  ISAAC  programme  has  demonstrated  that  it  is  fea-
ible  to  monitor  the  prevalence  and  severity  of  asthma,
hinoconjunctivitis,  and  eczema  in  children,  globally.  It  is
ossible  that  prevalence  of  current  symptoms  of  asthma
hinoconjunctivitis  and  eczema,  as  well  as  those  factors
hat  could  induce  changes  on  it,  may  behave  accord-
ngly  to  the  important  environmental  and  climatic  changes
resently  occurring  in  the  world.  ISAAC  Phase  Three  has
xtended,  updated  and  disseminated  valuable  epidemiolog-
cal  information  on  asthma,  rhinoconjunctivitis  and  eczema
n  childhood,  proposing  new  hypotheses,  contrasting  old
nes  and  modernising  the  basis  for  further  aetiological
c
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esearch  into  the  genetic,  lifestyle,  environmental,  clinical
nd  medical-care  factors  for  those  diseases.
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urrently  the  main  source  of  funding  for  the  ISAAC  Inter-
ational  Data  Centre  (IIDC)  is  the  New  Zealand  Lottery
oard.  Many  New  Zealand  funding  bodies  have  contributed
upport  for  the  IIDC  during  the  periods  of  ﬁeldwork  and
ata  compilation  (the  Health  Research  Council  of  New
ealand,  the  Asthma  and  Respiratory  Foundation  of  New
ealand,  the  Child  Health  Research  Foundation,  the  Hawke’s
ay  Medical  Research  Foundation,  the  Waikato  Medical
esearch  Foundation,  Glaxo  Wellcome  New  Zealand,  the
uckland  Medical  Research  Foundation  and  Astra  Zeneca
ew  Zealand).  Glaxo  Wellcome  International  Medical  Affairs
upported  the  regional  coordination  for  Phase  Three  and  the
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he  above,  ISAAC  would  not  have  been  such  a  global  success.
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SAAC  Steering  Committee:  N  Aït-Khaled*  (International
nion  Against  Tuberculosis  and  Lung  Disease  [The  Union],
heraga,  Algeria);  HR  Anderson  (Division  of  Community
ealth  Sciences,  St  Georges,  University  of  London,  Lon-
on,  UK);  MI  Asher  (Department  of  Paediatrics:  Child  and
outh  Health,  Faculty  of  Medical  and  Health  Sciences,  The
niversity  of  Auckland,  New  Zealand);  R  Beasley*  (Medi-
al  Research  Institute  of  New  Zealand,  Wellington,  New
ealand);  B  Björkstén*  (Institute  of  Environmental  Medicine,
arolinska  Institutet,  Stockholm,  Sweden);  B  Brunekreef
Institute  of  Risk  Assessment  Sciences,  Universiteit  Utrecht,
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The  Netherlands);  J  Crane  (Wellington  Asthma  Research
Group,  Wellington  School  of  Medicine,  New  Zealand);  P  Ell-
wood  (Department  of  Paediatrics:  Child  and  Youth  Health,
Faculty  of  Medical  and  Health  Sciences,  The  University  of
Auckland,  New  Zealand);  C  Flohr  (St  John’s  Institute  of
Dermatology,  St  Thomas’  Hospital,  London,  UK);  S  Foli-
aki*  (Centre  for  Public  Health  Research,  Massey  University,
Wellington,  New  Zealand);  F  Forastiere  (Department  of
Epidemiology,  Rome  E  Health  Authority,  Rome,  Italy);  L
García-Marcos  (Instituto  de  Salud  Respiratoria,  Universi-
dad  de  Murcia,  Spain);  U  Keil*  (Institut  für  Epidemiologie
und  Sozialmedizin,  Universität  Münster,  Germany);  CKW  Lai*
(Department  of  Medicine  and  Therapeutics,  The  Chinese
University  of  Hong  Kong,  SAR  China);  J  Mallol*  (Department
of  Pediatric  Respiratory  Medicine,  Hospital  CRS  El  Pino,  Uni-
versity  of  Santiago  de  Chile,  Chile);  EA  Mitchell  (Department
of  Paediatrics:  Child  and  Youth  Health,  Faculty  of  Medi-
cal  and  Health  Sciences,  The  University  of  Auckland,  New
Zealand);  S  Montefort*  (Department  of  Medicine,  University
of  Malta,  Malta),  J  Odhiambo*  (Centre  Respiratory  Diseases
Research  Unit,  Kenya  Medical  Research  Institute,  Nairobi,
Kenya);  N  Pearce  (Department  of  Medical  Statistics,  Fac-
ulty  of  Epidemiology  and  Public  Health,  London  School  of
Hygiene  and  Tropical  Medicine,  London,  UK);  CF  Robertson
(Murdoch  Children’s  Research  Institute,  Melbourne,  Aus-
tralia);  AW  Stewart  (Epidemiology  and  Biostatistics,  School
of  Population  Health,  The  University  of  Auckland,  New
Zealand);  D  Strachan  (Division  of  Community  Health  Sci-
ences,  St  Georges,  University  of  London,  London,  UK);  E
von  Mutius  (Dr  von  Haunerschen  Kinderklinik  de  Universität
München,  Germany);  SK  Weiland+ (Institute  of  Epidemiology,
University  of  Ulm,  Germany);  G  Weinmayr  (Institute  of  Epi-
demiology,  University  of  Ulm,  Germany);  H  Williams  (Centre
for  Evidence  Based  Dermatology,  Queen’s  Medical  Centre,
University  Hospital,  Nottingham,  UK);  G  Wong  (Department
of  Paediatrics,  Prince  of  Wales  Hospital,  Hong  Kong,  SAR
China).  *Regional  Coordinators +Deceased
ISAAC  International  Data  Centre:  MI  Asher,  TO  Clayton,  P
Ellwood,  EA  Mitchell,  E  Ellwood.  Department  of  Paediatrics:
Child  and  Youth  Health,  and  AW  Stewart,  School  of  Popu-
lation  Health,  Faculty  of  Medical  and  Health  Sciences,  The
University  of  Auckland,  New  Zealand.
ISAAC  Phase  Three  Collaborators:  Albania:  Prof  A
Priftanji*  (Tiranë);  Algeria:  Prof  B  Benhabylès  (Wilaya  of
Algiers);  Argentina:  Dr  CE  Baena-Cagnani*  (Córdoba),  Prof  Dr
CD  Crisci  (Rosario  City),  Dr  M  Gómez  (Salta),  Prof  GE  Zabert
(Neuquén);  Australia:  Prof  CF  Robertson*  (Melbourne);  Aus-
tria:  Assoc  Prof  G  Haidinger*  (Kärnten,  Urfahr-Umgebung);
Barbados:  Dr  ME  Howitt*  (Barbados);  Belgium:  Prof  J  Weyler
(Antwerp);  Bolivia:  Dr  R  Pinto-Vargas*  (Santa  Cruz);  Brazil:
Dr  CdSD  Bernhardt  (Itajaí),  Dr  WG  Borges  (Brasília),  Assoc
Prof  PAM  Camargos  (Belo  Horizonte),  Dra  MdS  Cardoso
(Manaus  Amazonas),  Prof  AJLAd  Cunha  (Nova  Iguac¸u), Dr  GB
Fischer  (Porto  Alegre),  Dr  JM  Motta  (Aracaju),  Prof  FJ  Passos
(Maceió),  Dr  AC  Pastorino  (São  Paulo  West),  Dr  AC  Porto
Neto  (Passo  Fundo),  Prof  N  Rosário  (Curitiba),  Assis  Prof  A
Silva  (Caruaru),  Prof  D  Solé*  (Rural  Santa  Maria,  Santa  Maria,
São  Paulo),  Assoc  Prof  N  Wandalsen  (Santo  Andre),  Dr  M  de
Britto  (Recife),  Assoc  Prof  L  de  Freitas  Souza  (Feira  de  San-
tana,  Salvador,  Vitória  da  Conquista);  Bulgaria:  Dr  T  Popov*
(Soﬁa);  Cameroon:  Prof  C  Kuaban*  (Yaounde);  Canada:
Prof  A  Ferguson  (Vancouver),  Prof  D  Rennie  (Saskatoon);
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hannel  Islands:  Ms  R  Goulding  (Jersey),  Dr  P  Standring
Guernsey);  Chile:  Dr  P  Aguilar  (South  Santiago),  Dr  L
marales  (Punta  Arenas),  Dr  LAV  Benavides  (Calama),  Dr  MA
alvo  (Valdivia),  Dra  A  Contreras  (Chiloe);  China:  Prof  Y-Z
hen*  (Beijing,  Tong  Zhou),  Assis  Prof  O  Kunii  (Tibet),  Dr  Q
i  Pan  (Wulumuqi),  Prof  N-S  Zhong  (Guangzhou);  Colombia:
r  G  Aristizábal  (Bogotá),  Dr  AM  Cepeda  (Barranquilla),  Dr
A  Ordon˜ez  (Cali);  Congo:  Prof  J  M’Boussa  (Brazzaville);
ook  Islands:  Dr  R  Daniel*  (Rarotonga);  Costa  Rica:  Dr  ME
oto-Quirós*  (Costa  Rica);  Cote  d’Ivoire:  Dr  BN  Kofﬁ*  (Urban
ote  d’Ivoire);  Croatia:  Dr  K  Lah  Tomulic  (Rijeka);  Cuba:  Dra
 Varona  Peréz*  (La  Habana);  Ecuador:  Dr  S  Barba*  (Quito),
r  C  Bustos  (Guayaquil);  Egypt:  Dr  ML  Naguib  (Cairo);  El
alvador:  Dr  M  Figueroa  Colorado*  (San  Salvador);  Estonia:
r  M-A  Riikjärv*  (Tallinn);  Ethiopia:  Assoc  Prof  K  Melaku
Addis  Ababa);  Fiji:  Dr  R Sa’aga-Banuve  (Suva);  Finland:  Dr
 Pekkanen*  (Kuopio  County);  Former  Yugoslav  Republic  of
acedonia  (FYROM):  Assoc  Prof  E  Vlaski*  (Skopje);  Gabon:
r  IE  Hypolite*  (Port-Gentil);  Georgia:  Dr  M  Gotua*  (Kutaisi);
ermany:  Prof  Dr  U  Keil*  (Münster);  Greece:  Assoc  Prof  J
sanakas  (Thessaloniki);  Honduras:  Dr  A  Bueso-Engelhardt*
San  Pedro  Sula);  Hong  Kong:  Prof  YL  Lau  (Hong  Kong),  Prof
 Wong  (Hong  Kong);  Hungary:  Dr  Z  Novák  (Szeged),  Dr
 Zsigmond*  (Svábhegy);  India:  Prof  S  Awasthi  (Lucknow),
ssoc  Prof  S  Bhave  (Rasta  Peth),  Prof  J  Chhatwal  (Lud-
iana),  Dr  NM  Hanumante  (Pune),  Dr  KC  Jain  (Jodhpur),
r  MK  Joshi  (Mumbai  (16)),  Dr  VA  Khatav  (Borivali),  Prof
 Kumar  (Chandigarh),  Dr  SN  Mantri  (Mumbai  (29)),  Dr  AV
herwani  (Mumbai  (18)),  Prof  S  Rego  (Bangalore),  Prof  M
abir  (Bikaner),  Dr  S  Salvi  (Nagpur,  Pimpri),  Dr  G  Setty
Chennai  (3)),  Prof  SK  Sharma  (New  Delhi  (7)),  Prof  V  Singh
Jaipur),  Dr  TU  Sukumaran  (Kottayam),  Dr  PS  Suresh  Babu
Davangere);  Indonesia:  Prof  Dr  CB  Kartasasmita  (Bandung),
rof  P Konthen  (Bali),  Dr  W  Suprihati  (Semarang);  Iran:
r  M-R  Masjedi*  (Birjand,  Rasht,  Tehran,  Zanjan);  Isle
f  Man:  Dr  A  Steriu  (Isle  of  Man);  Italy:  Dr  L  Armenio
Bari),  Dr  L  Bisanti  (Milano),  Dr  E  Bonci  (Cosenza),  Dr  E
hellini  (Firenze),  Dr  G  Ciccone  (Torino),  Dr  V  Dell’Orco
Colleferro-Tivoli),  Dr  F  Forastiere*  (Roma),  Dr  C  Galassi
Emilia-Romagna),  Dr  G  Giannella  (Mantova),  Dr  S  La  Grutta
Palermo),  Dr  MG  Petronio  (Empoli),  Dr  S  Piffer  (Trento),  Dr
 Sestini  (Siena);  Japan:  Dr  H  Odajima  (Fukuoka),  Prof  M
ohei  (Tochigi);  Jordan:  Dr  F  Abu-Ekteish  (Amman);  Kenya:
r  FO  Esamai  (Eldoret),  Dr  L  Ng’ang’a*  (Nairobi);  Kingdom
f  Tonga:  Dr  S  Foliaki  (Nuku’alofa);  Kuwait:  Dr  JA  al-Momen
Kuwait);  Kyrgyzstan:  Dr  C  Imanalieva*  (Balykchi,  Bishkek),
rof  S  Sulaimanov  (Jalalabat);  Latvia:  Dr  V  Svabe  (Riga);
ithuania:  Prof  J  Bojarskas  (Panevezys,  Siauliai),  Assoc  Prof
 Kudzyte*  (Kaunas);  Malaysia:  Assoc  Prof  BS  Quah  (Kota
haru),  Dr  KH  Teh  (Alor  Setar),  Assoc  Prof  J  de  Bruyne*
Klang  Valley);  Malta:  Prof  S  Montefort*  (Malta);  Mexico:  Dr
 Baeza-Bacab*  (Mérida),  Dra  M  Barragán-Meijueiro  (Ciudad
e  México  (3)),  Dra  BE  Del-Río-Navarro  (Ciudad  de  México
1)),  Dr  R  García-Almaráz  (Ciudad  Victoria),  Dr  SN  González-
íaz  (Monterrey),  Dr  FJ  Linares-Zapién  (Toluca),  Dr  JV
erida-Palacio  (Mexicali  Valley),  Dra  N  Ramírez-Chanona
Ciudad  de  México  (4)),  Dr  S  Romero-Tapia  (Villahermosa),
rof  I  Romieu  (Cuernavaca);  Morocco:  Prof  Z  Bouayad*
Benslimane,  Boulmene,  Casablanca,  Marrakech);  Nether-
ands:  Prof  R  Engels  (Netherlands);  New  Zealand:  Prof  MI
sher*  (Auckland),  Dr  R  MacKay  (Nelson),  Dr  C  Moyes  (Bay
f  Plenty),  Assoc  Prof  P Pattemore  (Christchurch),  Prof  N
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earce  (Wellington);  Nicaragua:  Dr  JF  Sánchez*  (Managua);
igeria:  Prof  BO  Onadeko  (Ibadan);  Niue:  Ms  M  Magato-
ia  (Niue  Island);  Nouvelle  Caledonie:  Dr  I  Annesi-Maesano
Nouvelle  Caledonie);  Pakistan:  Dr  N  Mahmood*  (Karachi),  Dr
O  Yusuf  (Islamabad);  Palestine:  Dr  N  El  Sharif*  (Ramallah),
r  S  Mortaja  (North  Gaza);  Panama:  Dr  G  Cukier*  (David-
anamá);  Paraguay:  Dr  JA  Guggiari-Chase*  (Asunción);  Peru:
r  P  Chiarella*  (Lima);  Philippines:  Prof  F  Cua-Lim*  (Metro
anila);  Poland:  Assoc  Prof  A  Brêborowicz  (Poznan),  Assoc
rof  G  Lis*  (Kraków);  Polynesie  Francaise:  Dr  I Annesi-
aesano  (Polynesie  Francaise);  Portugal:  Dr  ML  Chiera
Coimbra),  Dra  R  Câmara  (Funchal),  Dr  JM  Lopes  dos  Santos
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ondiourina  (Novosibirsk);  République  de  Guinée:  Prof  OY
ow  (Conakry);  Samoa:  Ms  P  Fuimaono  V  Pisi  (Apia);  Serbia
nd  Montenegro:  Dr  O  Adzovic  (Podgorica),  Dr  M  Hadnadjev
Novi  Sad),  Dr  E  Panic  (Sombor),  Dr  S  Zivanovic  (Nis),  Dr  Z
ivkovic*  (Belgrade);  Singapore:  Assoc  Prof  DYT  Goh  (Singa-
ore);  South  Africa:  Prof  K  Voyi  (Polokwane),  Prof  HJ  Zar*
Cape  Town);  South  Korea:  Prof  H-B  Lee*  (Provincial  Korea,
eoul);  Spain:  Dr  A  Arnedo-Pena  (Castellón),  Dr  J  Batlles-
arrido  (Almeria),  Prof  A  Blanco-Quirós  (Valladolid),  Dr  RM
usquets  (Barcelona),  Dr  I  Carvajal-Uruen˜a  (Asturias),  Dr  G
arcía-Hernández  (Madrid),  Prof  L  García-Marcos*  (Carta-
ena),  Dr  C  González  Díaz  (Bilbao),  Prof  F  Guillén-Grima
Pamplona),  Dr  A  López-Silvarrey  Varela  (A  Corun˜a),  Prof
M  Morales  Suárez-Varela  (Valencia),  Prof  EG  Pérez-Yarza
San  Sebastián);  Sri  Lanka:  Dr  KD  Gunasekera*  (Sri  Lanka);
udan:  Prof  OAA  Musa  (Khartoum);  Sultanate  of  Oman:  Assoc
rof  O  Al-Rawas*  (Al-Khod);  Sweden:  Dr  H  Vogt  (Linköping);
yrian  Arab  Republic:  Dr  S  Mohammad*  (Tartous),  Prof  Y
ohammad  (Lattakia),  Dr  K  Tabbah  (Aleppo);  Taiwan:  Dr  J-L
uang*  (Taipei),  Dr  C-C(Kao  (Taoyuan);  Thailand:  Dr  A  Kong-
anichkul  (Nakorn  Pathom),  Dr  R  Nettagul  (Chiangrai),  Dr  T
rasarnphanich  (Chantaburi),  Assoc  Prof  J  Teeratakulpisarn
Khon  Kaen),  Assoc  Prof  M  Trakultivakorn  (Chiang  Mai),
r  P  Vichyanond*  (Bangkok);  Togo:  Prof  O  Tidjani  (Lome);
okelau:  Dr  T  Iosefa*  (Tokelau);  Trinidad  and  Tobago:  Dr
A  Monteil  (St  Augustine,  Tobago);  Tunisia:  Prof  M  Jerray
Sousse),  Prof  F  Khaldi  (Grand  Tunis);  USA:  Prof  GJ  Redding
Seattle),  Dr  HH  Windom  (Sarasota),  Dr  K  Yeatts  (Chapel
ill);  Ukraine:  Assoc  Prof  V  Ognev*  (Kharkiv,  Rural  Kharkiv);
nited  Kingdom:  Prof  HR  Anderson*  (North  Thames,  South
hames),  Dr  JB  Austin  (Scotland),  Dr  M  Burr  (Wales),  Dr  MH
hamssain  (Sunderland),  Prof  D  Strachan  (Surrey/Sussex);
ruguay:  Dra  D  Holgado*  (Montevideo),  Dra  MC  Lapides
Paysandú);  Venezuela:  Dr  O  Aldrey*  (Caracas);  Vietnam:  Dr
 Vaên  Cam  (Ho  Chi  Minh  City).  *National  Coordinator
ISAAC  Phase  Three  National  Coordinators  not  identiﬁed
bove:  MR  Sears  (Canada),  HR  Anderson  (Channel  Islands),  V
guirre  (Chile),  J  Mallol  (Colombia,  interim),  V  Ahel  (Croa-
ia),  L  Waqatakirewa  (Fiji),  C  Gratziou  (Greece),  CKW  Lai
Hong  Kong),  HR  Anderson  (Isle  of  Man),  J  Shah  (India),  K
aratawidjaja  (Indonesia),  S  Nishima  (Japan),  T  Fakakovi
Kingdom  of  Tonga),  R  Otten  (Netherlands),  S  Barny  (Nou-
elle  Caledonie),  R  Chansin  (Polynesie  Francaise),  P  Manning
Republic  of  Ireland),  JP  Okiata  (Republique  Democratique
u  Congo),  C  Catteau  (Reunion  Island),  RM  Khaitov  (Russia),
1J.  Mallol  et  al.
 Tuuau-Potai  (Samoa),  B  Lee  (Singapore),  A  El  Sony  (Sudan),
 Nilsson  (Sweden).
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